美国上市药品(最近批准)
按批准日期最近更新
| 药品名称 | 商品名 | 申请号 | 产品编号 | 剂型 | 规格 | 企业 | 市场状态 | 批准日期 | 上市日期 |
|---|---|---|---|---|---|---|---|---|---|
| PITOLISANT | PITOLISANT | ANDA218832 | 001 | TABLET | 4.45MG | ANNORA PHARMA PRIVATE LIMITED | None (Tentative Approval) | 2026-10-08 | 2026-10-08 |
| PITOLISANT | PITOLISANT | ANDA218832 | 002 | TABLET | 17.8MG | ANNORA PHARMA PRIVATE LIMITED | None (Tentative Approval) | 2026-10-08 | 2026-10-08 |
| BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE | BREZTRI AEROSPHERE | NDA220290 | 001 | INHALANT;ORAL | 160MCG/9MCG/4.8MCG | ASTRAZENECA AB | Prescription | 2026-10-08 | 2026-10-08 |
| OLANZAPINE | WELTRUZA | NDA219007 | 001 | SUSPENSION, EXTENDED RELEASE;INJECTABLE | 318MG | TEVA NEUROSCIENCE INC | Prescription | 2026-10-08 | 2026-10-08 |
| OLANZAPINE | WELTRUZA | NDA219007 | 002 | SUSPENSION, EXTENDED RELEASE;INJECTABLE | 425MG | TEVA NEUROSCIENCE INC | Prescription | 2026-10-08 | 2026-10-08 |
| OLANZAPINE | WELTRUZA | NDA219007 | 003 | SUSPENSION, EXTENDED RELEASE;INJECTABLE | 531MG | TEVA NEUROSCIENCE INC | Prescription | 2026-10-08 | 2026-10-08 |
| MIRABEGRON | MIRABEGRON | ANDA219599 | 001 | TABLET, EXTENDED RELEASE;ORAL | 25MG | CREEKWOOD PHARMS | Prescription | 2026-10-07 | 2026-10-07 |
| MIRABEGRON | MIRABEGRON | ANDA219599 | 002 | TABLET, EXTENDED RELEASE;ORAL | 50MG | CREEKWOOD PHARMS | Prescription | 2026-10-07 | 2026-10-07 |
| HYDROCHLOROTHIAZIDE | HYDROCHLOROTHIAZIDE | ANDA218248 | 001 | SOLUTION;ORAL | 50MG/5ML | RUBICON RESEARCH | Prescription | 2026-10-07 | 2026-10-07 |
| FIDAXOMICIN | FIDAXOMICIN | ANDA219737 | 001 | TABLET;ORAL | 200MG | HIKMA PHARMS | Prescription | 2026-10-07 | 2026-10-07 |
上一页 第 1 / 3 页 下一页